New hope for rare skin disease: bimzelx trial launches
NCT ID NCT07497620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug Bimzelx (bimekizumab) can improve skin symptoms in adults with pityriasis rubra pilaris, a rare condition causing red, scaly patches. Researchers will enroll 12 participants and measure how many achieve at least 75% improvement in skin severity after 24 weeks. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.